, /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on , at U.S.
Eastern Time. BrainStorm's President and Chief Executive Officer, , will present the update, together with recently appointed Chief Operating Officer and EVP, , PhD. Bob Dagher, MD, Chief Development Officer, will also be on the call for Q&A.
The Q&A session with the investment community will follow the prepared remarks. Participants are encouraged to submit their questions in advance of the call by sending them to: . Questions should be submitted by 10:00 a.
m. Eastern Time on . The investment community may participate in the conference call by dialing the following numbers: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 358402 Webcast: Those that wish to listen to the replay of the conference call can do so by dialing the numbers below.
The replay will be available until . : Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 50824 . BrainStorm Cell Therapeutics is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
BrainStorm Cell Therapeutics holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells.